Related Experiment Video
Updated: Dec 21, 2025
08:23
Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
4.6K
Nitric Oxide in Post-cardiac Arrest Syndrome
Yusuke Miyazaki1, Fumito Ichinose
1Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Journal of Cardiovascular Pharmacology
|May 19, 2020
Summary
Therapeutic interventions increasing nitric oxide (NO) bioavailability, particularly NO inhalation therapy, show promise for improving neurological outcomes and survival in patients experiencing post-cardiac arrest syndrome (PCAS). Further clinical studies are needed.
Area of Science:
- Cardiovascular Medicine
- Critical Care Medicine
- Neuroscience
Background:
- Sudden cardiac arrest (SCA) remains a major global cause of death.
- Survivors often experience neurological deficits due to post-cardiac arrest syndrome (PCAS).
- PCAS pathogenesis involves vascular endothelial dysfunction, platelet activation, and systemic inflammation.
Purpose of the Study:
- To investigate the role of nitric oxide (NO)-dependent signaling in PCAS.
- To evaluate the potential of therapeutic interventions that enhance NO bioavailability for improving outcomes after cardiac arrest.
Main Methods:
- Review of preclinical and clinical studies on NO-dependent signaling in PCAS.
- Focus on therapeutic strategies, including NO inhalation therapy.
- Assessment of neurological outcomes and survival rates in relevant models and patient populations.
Main Results:
- Endothelial-derived NO is crucial for vascular homeostasis.
- Preclinical studies demonstrate that increasing NO bioavailability improves outcomes in PCAS models.
- NO inhalation therapy has shown efficacy in improving neurological outcomes and survival in various species.
Conclusions:
- Therapeutic strategies aimed at increasing NO bioavailability hold significant potential for managing PCAS.
- NO inhalation therapy is a promising intervention for improving neurological recovery and survival post-cardiac arrest.
- Clinical trials are essential to confirm the safety and efficacy of inhaled NO in PCAS patients.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
6.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.0K
01:16Antianginal Drugs: Nitrates and β-Blockers
1.2K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.2K
01:28Acute Coronary Syndrome IV: Interprofessional Care
161
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
161
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
423
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
423
01:23Antihypertensive Drugs: Vasodilators
1.9K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
01:26Acute Coronary Syndrome V: Nursing Management
198
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
198